The Egyptian Stock Exchange announced the end of the distribution right of 3.5 EGP for shares of the Egyptian International Pharmaceutical Industries Company 'EIPICO' at the close of today's session, April 27. This decision follows the approval of the company's General Assembly regarding the board's proposal for profit distributions for the fiscal year ending in December 2025.
The distribution of coupon number (40) will be 3.5 EGP per share, to be paid in two separate installments. The first installment of 1.5 EGP will begin distribution on April 30, 2026, while the second installment of 2 EGP will commence on September 30, 2026.
Details of the Event
The General Assembly also approved the annual financial statements for the year 2025, where the distributable net profit reached approximately 1.327 billion EGP. The distribution structure is as follows: shareholders' share 590.64 million EGP, employees' share 108.3 million EGP, legal reserve 56.26 million EGP, board of directors' bonus 12 million EGP, and retained earnings 560.2 million EGP.
Additionally, the assembly ratified the board of directors' report on the company's activities and the governance report for the year 2025, as well as discharging the board of directors for the concluded financial period.
Background & Context
'EIPICO' has achieved significant growth in its profits, rising by 33% last year to reach 1.45 billion EGP, compared to a profit of 1.09 billion EGP at the end of 2024. The company's sales also increased to 9.44 billion EGP, up from 7.59 billion EGP during 2024.
During the first nine months of last year, profits rose by 17% to reach 1.16 billion EGP, with sales amounting to 7.15 billion EGP. In the first half of last year, the company recorded profits of 828 million EGP, an increase of 6% compared to the same period in 2024.
Impact & Consequences
The profit distributions are a positive step reflecting the company's strong performance, enhancing investor confidence in the Egyptian market. Furthermore, the increase in profits and sales indicates the success of the company's strategies for expansion and growth.
'EIPICO' is currently working to complete the final phase of the 'EIPICO 3' factory project, which is among the significant projects in the sector of producing biological products and biosimilars. The factory will enhance the company's capacity to meet local and international market needs.
Regional Significance
'EIPICO' is considered one of the leading companies in the pharmaceutical industry in Egypt, and its success reflects the growing sector of pharmaceutical industries in the region. The new project will contribute to localizing the pharmaceutical industry in Egypt, enhancing the country's ability to provide medicines at reasonable prices.
In conclusion, these developments reflect 'EIPICO's' commitment to strengthening its market position and providing high-quality products that meet citizens' needs.